Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeuticsâ¢, today reported its financial results for the first quarter ended March 31, 2013.
Targacept reported a net loss of $8.1 million for the first ...
[Published BioSpace - May 07 2013]